Glucagon-like peptide-1 receptor agonists for the treatment of opioid use disorders: a systematic review
Acta Neuropsychiatrica · 2025 · 37
DOI: 10.1017/neu.2025.10038 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Acta Neuropsychiatrica, online erschienen am 03.09.2025. Verfasst von Hezekiah C T Au und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medical Science, University of Toronto, Toronto, ON, Canada. Hauptthemen laut MEDLINE: Exenatide, Glucagon-Like Peptide 1, Glucagon-Like Peptide-1 Receptor Agonists, Liraglutide. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Extant literature indicated that glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may potentially reduce risk of opioid overdose in persons with opioid use disorders (OUDs). Herein, we conducted a comprehensive synthesis of the effects of GLP-1 and GLP-1 RAs on OUDs.
Methods
We examined preclinical and clinical paradigms examining the effects of GLP-1 and GLP-1 RAs on OUD and OUD-associated behaviours (i.e. opioid self-administration, opioid-seeking behaviour). Relevant articles were retrieved from OVID (MedLine, Embase, AMED, PsychINFO, and JBI EBP Database), PubMed, and Web of Science from database inception to 1 May 2025. Primary studies ( n = 10) examining the aforementioned effects associated with GLP-1 and GLP-1 RA administration were retrieved for analysis.
Results
GLP-1 RAs (i.e. exenatide, liraglutide) reduced opioid-seeking behaviour ( p < 0.05) and self-administration of opioid drugs ( p < 0.05) in preclinical paradigms. In addition, results from human studies indicate that GLP-1 administration was associated with reducing the risk of opioid overdose in human studies (aIRR = 0.60, 95% CI [0.43, 0.83]).
Conclusion
GLP-1 RAs may affect opioid self-administration as well as the risk for overdose as evidenced by both preclinical and clinical data. There is a need for adequate well-controlled studies to determine whether GLP-1 RAs may provide clinically meaningful improvement and risk reduction in persons living with OUDs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Medical Science, University of Toronto, Toronto, ON, Canada.
- Brain and Cognition Discovery Foundation, Toronto, ON, Canada.
- Institute of Epidemiology and Health Care, University College London, London, UK.
- Mood Disorders Psychopharmacology Unit, Toronto, ON, Canada.
- Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.
- Department of Pharmacology & Toxicology, University of Toronto, Toronto, ON, Canada.
ORCID-Profile: Hezekiah C T Au, Roger S McIntyre
Zitieren
APA
Au, H. C. T., Lam, P. H., Kabir, F., Huang, C. L., Dri, C. E., Le, G. H., Kwan, A. T. H., Wong, S., Teopiz, K. M., & McIntyre, R. S. (2025). Glucagon-like peptide-1 receptor agonists for the treatment of opioid use disorders: a systematic review. Acta Neuropsychiatrica, 37. https://doi.org/10.1017/neu.2025.10038
Vancouver
Au HCT, Lam PH, Kabir F, Huang CL, Dri CE, Le GH, et al. Glucagon-like peptide-1 receptor agonists for the treatment of opioid use disorders: a systematic review. Acta Neuropsychiatrica. 2025;37. doi:10.1017/neu.2025.10038
BibTeX
@article{Au2025,
author = {Au, Hezekiah C T and Lam, Pak Ho and Kabir, Fateen and Huang, Chen Lily and Dri, Christine E and Le, Gia Han and Kwan, Angela T H and Wong, Sabrina and Teopiz, Kayla M and McIntyre, Roger S},
title = {Glucagon-like peptide-1 receptor agonists for the treatment of opioid use disorders: a systematic review},
journal = {Acta Neuropsychiatrica},
year = {2025},
volume = {37},
doi = {10.1017/neu.2025.10038}
}
EUVIMED